Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Non-cash Items (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Non-cash Items for 7 consecutive years, with $63.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-cash Items fell 35.12% to $63.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $63.4 million, a 35.12% decrease, with the full-year FY2025 number at $63.4 million, down 35.12% from a year prior.
  • Non-cash Items was $63.4 million for Q4 2025 at Kymera Therapeutics, up from $7.0 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $246.9 million in Q4 2021 to a low of $1.6 million in Q1 2021.
  • A 5-year average of $66.2 million and a median of $60.2 million in 2024 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: crashed 95.97% in 2022, then skyrocketed 3161.35% in 2024.
  • Kymera Therapeutics' Non-cash Items stood at $246.9 million in 2021, then crashed by 77.35% to $55.9 million in 2022, then fell by 11.28% to $49.6 million in 2023, then surged by 96.92% to $97.7 million in 2024, then tumbled by 35.12% to $63.4 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Non-cash Items are $63.4 million (Q4 2025), $7.0 million (Q3 2025), and $134.2 million (Q2 2025).